GB1446536A - Pharmaceutically active compositions - Google Patents
Pharmaceutically active compositionsInfo
- Publication number
- GB1446536A GB1446536A GB729975A GB729975A GB1446536A GB 1446536 A GB1446536 A GB 1446536A GB 729975 A GB729975 A GB 729975A GB 729975 A GB729975 A GB 729975A GB 1446536 A GB1446536 A GB 1446536A
- Authority
- GB
- United Kingdom
- Prior art keywords
- carcinoma
- antibody
- pharmaceutically active
- agent
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title 1
- 201000009030 Carcinoma Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 abstract 2
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 abstract 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 abstract 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 abstract 1
- -1 adrimycin Chemical compound 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 150000008209 arabinosides Chemical class 0.000 abstract 1
- 201000008275 breast carcinoma Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940104302 cytosine Drugs 0.000 abstract 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960000485 methotrexate Drugs 0.000 abstract 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 abstract 1
- 201000008968 osteosarcoma Diseases 0.000 abstract 1
- 229960003171 plicamycin Drugs 0.000 abstract 1
- 210000001550 testis Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB729975A GB1446536A (en) | 1975-02-21 | 1975-02-21 | Pharmaceutically active compositions |
| DE19752507901 DE2507901A1 (de) | 1975-02-21 | 1975-02-24 | Pharmazeutisches praeparat zur krebsbehandlung und verfahren zu dessen herstellung |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB729975A GB1446536A (en) | 1975-02-21 | 1975-02-21 | Pharmaceutically active compositions |
| DE19752507901 DE2507901A1 (de) | 1975-02-21 | 1975-02-24 | Pharmazeutisches praeparat zur krebsbehandlung und verfahren zu dessen herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1446536A true GB1446536A (en) | 1976-08-18 |
Family
ID=38878533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB729975A Expired GB1446536A (en) | 1975-02-21 | 1975-02-21 | Pharmaceutically active compositions |
Country Status (2)
| Country | Link |
|---|---|
| DE (1) | DE2507901A1 (enrdf_load_stackoverflow) |
| GB (1) | GB1446536A (enrdf_load_stackoverflow) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1979000515A1 (en) * | 1978-01-16 | 1979-08-09 | Univ Boston | Method of effecting cellular uptake of molecules |
| FR2437213A1 (fr) * | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
| FR2466252A2 (fr) * | 1979-10-03 | 1981-04-10 | Clin Midy | Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine |
| EP0056322A1 (en) * | 1981-01-12 | 1982-07-21 | Lilly Industries Limited | Immunoglobulin conjugates |
| EP0088695A3 (en) * | 1982-03-09 | 1986-01-29 | Cytogen Corporation | Antibody conjugates |
| DE3513572A1 (de) * | 1985-04-16 | 1986-10-16 | Karl Prof. Dr.med. 7302 Ostfildern Theurer | Herstellung von praeparaten zur spezifischen beeinflussung der humoralen und zellulaeren immunreaktion |
| US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| EP0234151A1 (fr) * | 1985-12-20 | 1987-09-02 | Sanofi | Glycoprotéines modifiées par oxydation et formation de base de Schiff, inhibant les ribosomes, procédé d'obtention et immunotoxines comprenant une telle glycoprotéine |
| US4701521A (en) * | 1978-07-17 | 1987-10-20 | The Trustees Of Boston University | Method of effecting cellular uptake of molecules |
| US4801688A (en) * | 1986-05-27 | 1989-01-31 | Eli Lilly And Company | Hydrazone immunoglobulin conjugates |
| US4814438A (en) * | 1986-12-24 | 1989-03-21 | Eli Lilly And Company | Immunoglobulin conjugates of 2',2'-difluronucleosides |
| US4867973A (en) * | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US4994558A (en) * | 1986-12-24 | 1991-02-19 | Eli Lilly And Company | Immunoglobulin conjugates |
| US5140104A (en) * | 1982-03-09 | 1992-08-18 | Cytogen Corporation | Amine derivatives of folic acid analogs |
| WO2014093652A1 (en) * | 2012-12-14 | 2014-06-19 | University Of Kentucky Research Foundation | Semi - synthetic mithramycin derivatives with anti-cancer activity |
| US9447135B2 (en) | 2012-12-14 | 2016-09-20 | University Of Kentucky Research Foundation | Semi-synthetic mithramycin derivatives with anti-cancer activity |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL47372A (en) * | 1975-05-27 | 1979-10-31 | Yeda Res & Dev | Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same |
| US7220854B1 (en) | 1982-06-23 | 2007-05-22 | Enzo Life Sciences, Inc. C/O Enzo Biochem, Inc. | Sugar moiety labeled nucleotide, and an oligo- or polynucleotide, and other compositions comprising such sugar moiety labeled nucleotides |
| CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1792298A1 (de) * | 1968-08-16 | 1971-07-08 | Rand Dev Corp | Immunochromatographische Verteilung von loeslichen Antigenen |
| DE2324544A1 (de) * | 1972-05-15 | 1973-11-29 | Biological Developments | Synthetische antigene und ihre verwendung |
-
1975
- 1975-02-21 GB GB729975A patent/GB1446536A/en not_active Expired
- 1975-02-24 DE DE19752507901 patent/DE2507901A1/de active Granted
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1979000515A1 (en) * | 1978-01-16 | 1979-08-09 | Univ Boston | Method of effecting cellular uptake of molecules |
| US4701521A (en) * | 1978-07-17 | 1987-10-20 | The Trustees Of Boston University | Method of effecting cellular uptake of molecules |
| FR2437213A1 (fr) * | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
| FR2466252A2 (fr) * | 1979-10-03 | 1981-04-10 | Clin Midy | Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine |
| EP0056322A1 (en) * | 1981-01-12 | 1982-07-21 | Lilly Industries Limited | Immunoglobulin conjugates |
| EP0088695A3 (en) * | 1982-03-09 | 1986-01-29 | Cytogen Corporation | Antibody conjugates |
| US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US5140104A (en) * | 1982-03-09 | 1992-08-18 | Cytogen Corporation | Amine derivatives of folic acid analogs |
| US4867973A (en) * | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| DE3513572A1 (de) * | 1985-04-16 | 1986-10-16 | Karl Prof. Dr.med. 7302 Ostfildern Theurer | Herstellung von praeparaten zur spezifischen beeinflussung der humoralen und zellulaeren immunreaktion |
| EP0234151A1 (fr) * | 1985-12-20 | 1987-09-02 | Sanofi | Glycoprotéines modifiées par oxydation et formation de base de Schiff, inhibant les ribosomes, procédé d'obtention et immunotoxines comprenant une telle glycoprotéine |
| US4801688A (en) * | 1986-05-27 | 1989-01-31 | Eli Lilly And Company | Hydrazone immunoglobulin conjugates |
| US4814438A (en) * | 1986-12-24 | 1989-03-21 | Eli Lilly And Company | Immunoglobulin conjugates of 2',2'-difluronucleosides |
| US4994558A (en) * | 1986-12-24 | 1991-02-19 | Eli Lilly And Company | Immunoglobulin conjugates |
| WO2014093652A1 (en) * | 2012-12-14 | 2014-06-19 | University Of Kentucky Research Foundation | Semi - synthetic mithramycin derivatives with anti-cancer activity |
| US9447135B2 (en) | 2012-12-14 | 2016-09-20 | University Of Kentucky Research Foundation | Semi-synthetic mithramycin derivatives with anti-cancer activity |
Also Published As
| Publication number | Publication date |
|---|---|
| DE2507901C2 (enrdf_load_stackoverflow) | 1990-02-01 |
| DE2507901A1 (de) | 1976-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1446536A (en) | Pharmaceutically active compositions | |
| GB1523980A (en) | Therapeutic agents | |
| EG18751A (en) | Antibody - enzime conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells | |
| GEP20033094B (en) | Steroid Sulphatase Inhibitors | |
| ES2134294T3 (es) | Reactividad inmune para oncogenes expresados activos para la diagnosis y el tratamiento de tumores malignos. | |
| IL87885A0 (en) | Compounds having antiprogestational and anti-estrogenic activities for the treatment of tumours | |
| DE69631975D1 (de) | Discodermolide verbindungen und deren pharmazeutische zusammensetzungen zur krebstherapie | |
| IL97776A0 (en) | Antibody conjugates for treatment of neoplastic diseases | |
| BG42837A3 (bg) | Метод за получаване на имуноглобулинови производни на винка алкалоиди | |
| ES444494A1 (es) | Procedimiento para la preparacion de antracicliononas opti- camente activas. | |
| EP0194851A3 (en) | Human tumor therapy | |
| CA989404A (fr) | N-tertiaire aminomethyl-4' dibenzo(b,e)oxepine-11 spiro-2'-dioxolanne-1',3', leur procede de preparation et leur application en therapeutique | |
| GB1166110A (en) | Substituted Thiocyano Pyrroles, Fungicidal preparations containing these Compounds as Active Ingredients and methods of using the same | |
| GB1475651A (en) | Pharmaceutical composition for the treatment of cancer | |
| DE59712247D1 (de) | Mammakarzinom-assoziiertes gen | |
| GB1303194A (enrdf_load_stackoverflow) | ||
| CA1003787A (en) | Shielded, adustable depth minute particle stratifier | |
| GB1254948A (en) | Antivirial substance | |
| KR930700154A (ko) | 생물학적 활성 항-종양 항체와 화학요법의 병용에 의한 상승 효과적 종양치료법 | |
| GR16187B (el) | Μεθοδος δια την κατασκευην παρασκευασματος εχοντος θεραπευτικην ενεργειαν. | |
| GB1244437A (en) | Improvements in or relating to a dioxolan derivative and its use in pharmaceutical preparations | |
| GB1431099A (en) | Therapeutic composition containing isoxanthopterin | |
| ES459256A1 (es) | Un metodo de preparacion de 3-(3-carboxi-4-hidroxifenil)-4,5-dihidro-2-fenilbenz(e)indol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |